| abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to azaadamantane derivatives of formula (I), to their pharmaceutically acceptable salts possessing the properties of nAChR ligands, their application, a method of treating and based pharmaceutical compositions, and also to intermediate compounds of formula (VI) and (VII) and to application of the compound of formula (V) for preparing the compound (I). In general formulas n n n n n n n L 1 represents -O- or -NR a -; A represents -Ar 1 or -Ar 2 -L 2 - Ar 3 ; Ar 1 represents 5-9-member heteroaryl wherein said heteroaryl is optionally substituted by alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, carboxy, carboxyalkyl, cyano, halogenalkoxy, halogenalkyl, halogen, hydroxy, nitro, -NH 2 , (NH 2 )carbonyl and oxido; Ar 2 represents 5-6-member heteroaryl wherein said heteroaryl is optionally substituted by alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, carboxy, carboxy alkyl, cyano, halogenalkoxy, halogenalkyl, halogen, hydroxy, nitro, -NH 2 and (NH 2 ) carbonyl; Ar 3 represents aryl, optionally substituted alkoxy, alkoxyhalogenalkyl, alkyl, aryl, halogenalkoxy, halogen, hydroxy and -NH 2 ; or Ar 3 5-9-member heteroaryl wherein said heteroaryl is optionally substituted by alkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, aryl, carboxy, carboxyalkyl, halogenalkyl, heterocyclyl and tritylaryl; L 2 represents a bond, -O- or -C(O)NR a -; and R a represents hydrogen. n EFFECT: preparing the pharmaceutically acceptable salts possessing the properties of nAChR ligands. n 41 cl, 11 dwg, 162 ex |